Feature | July 06, 2020

Most Popular Cardiology Technology Content in June 2020

This is the most popular cardiac technology news content from the past month according to reader pageview analytics

Three of the most popular cardiovascular technologies to make news in June 2020. Top is the Impella Expandable Cardiac Pump (ECP) that is about to enter U.S. feasibility trials.Bottom left, the Foldax heart valve uses a flexible man-made material for valve leaflets rather than animal pericardium tissue. The hope is this new type of surgical and transcatheter aortic valve replacements (TAVR) device will enhance longevity of the valve leaflets. Bottom right, the SMT Hydra TAVR valve is the first Indian-made s

Three of the most popular cardiovascular technologies to make the top news in June 2020. Top is the Impella Expandable Cardiac Pump (ECP) that is about to enter U.S. feasibility trials.Bottom left, the Foldax heart valve uses a flexible man-made material for valve leaflets rather than animal pericardium tissue. The hope is this new type of surgical and transcatheter aortic valve replacements (TAVR) device will enhance longevity of the valve leaflets. Bottom right, the SMT Hydra TAVR valve is the first Indian-made structural heart devices to gain European CE mark approval.

July 6, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of June 2020. This is based on the website’s 267,198 pageviews for the month. While COVID-19 topics still are among the popular topics on the list, there has been a noticable return to normal reader interest in new cardiovascular technologies.
 

1. Kawasaki-like Inflammatory Disease Affects Children With COVID-19

2. The Cardiovascular Impact of COVID-19

3. FDA Approves First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

4. New Technologies Take Cardiac CT to the Next Level

5. SMT Hydra TAVR System Receives European CE Mark Approval

6. Foldax Gets $20 Million to Finance Innovative Heart Valve Technology

7. ASE Guidelines for the Protection of Echocardiography Providers During the COVID-19 Outbreak

8. Impella RP Granted FDA Emergency Use Authorization for COVID-19 Patients With Right Heart Failure

9. FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

10. First Implantation of Carmat Total Artificial Heart in Denmark 

11. Pulsed Field Ablation Successfully Treats Atrial Fibrillation

12. FDA Grants Breakthrough Device Designation for preCardia Catheter-based Heart Failure Treatment

13. New Heart Failure Devices and Drugs to Treat Heart Failure

14. WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

15. New Guideline Outlines Use of Transesophageal Echo to Assist Surgical Decision-making 

16. Use of Ultrasound to Improve Vascular Access

17. VIDEO: Demonstration of Abiomed Impella ECP 9 French Transcatheter Ventricular Assist Device

18. FDA Clears Scoring Sheath That Fits Over Standard Angioplasty Balloons

19. VIDEO: Top New EP Technologies at Heart Rhythm Society 2020

20. New Data Confirms Majority of Americans Avoiding Treatment for Heart Attack and Stroke Due to COVID-19

21. Edwards Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe

22. Biotronik Launches His-Bundle Pacing Tools

23. Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

24. Cardiac Imaging Best Practices During the COVID-19 Pandemic 

25. COVID-19 Genetic PCR Tests Give False Negative Results if Used Too Early
 

Related Popular Cardiology Content:

Most Popular Cardiology Technology Content in May 2020

Most Popular Cardiology Technology Content in March 2020

Most Popular Cardiology Technology Content in February 2020

Most Popular Cardiology Technology Content in January 2020

Top 25 Cardiology Videos on DAIC in 2019

The Most Popular Cardiology Topics in 2019

Most Popular Cardiology Technology Content in November 2019

Related Content

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

Feature | Heart Valve Technology | July 08, 2021
July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valv
The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.